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Abstract
Background: Shigella flexneri is the major pathogen causing bacillary dysentery. Fifteen serotypes have been
recognized up to now. The genesis of new S. flexneri serotypes is commonly mediated by serotype-converting
bacteriophages. Untypeable or novel serotypes from natural infections had been reported worldwide but have not
been generated in laboratory.
Results: A new S. flexneri serotype-serotype 1 d was generated when a S. flexneri serotype Y strain (native LPS) was
sequentially infected with 2 serotype-converting bacteriophages, SfX first and then SfI. The new serotype 1 d strain
agglutinated with both serotype X-specific anti-7;8 grouping serum and serotype 1a-specific anti- I typing serum,
and differed from subserotypes 1a, 1b and 1c. Twenty four S. flexneri clinical isolates of serotype X were all
converted to serotype 1 d by infection with phage SfI. PCR and sequencing revealed that SfI and SfX were
integrated in tandem into the proA-yaiC region of the host chromosome.
Conclusions: These findings suggest a new S. flexneri serotype could be created in nature. Such a conversion may
be constrained by susceptibility of a strain to infection by a given serotype-converting bacteriophage. This finding
has significant implications in the emergence of new S. flexneri serotypes in nature.
Background
Shigella is the primary pathogen causing bacillary dysen-
tery in developing countries. There are an estimated
164.7 million people worldwide infected by Shigella
annually; resulting in 1.1 million deaths, most being
children under five years [1]. A more recent study esti-
mated approximately 125 million annual shigellosis
cases and 14,000 related deaths in Asia [2], suggesting
that the death rate has decreased significantly in recent
years. Among the four Shigella species, S. dysenteriae, S.
flexneri, S. boydii,a n dS. sonnei, S. flexneri is the predo-
minant species [3].
S. flexneri serotyping are based on structure of the O-
antigen lipopolysaccharide. There are 15 known sero-
t y p e s :1 a ,1 b ,1 c ,2 a ,2 b ,3 a ,3 b ,4 a ,4 b ,5 a ,5 b ,6 ,X ,X v
and Y [4,5]. Except for serotype 6, all share a common
tetrasaccharide backbone of repeating units of N-acetyl-
glucosamine-rhamnose-rhamnose-rhamnose [6]. By add-
ing glucosyl and/or O-acetyl groups to one or more of
the sugars on the tetrasaccharide unit, various serotypes
are formed. Serotype Y possesses the primary basic O-
antigen without any modification of the tetrasaccharide
backbone [6].
It is well known that S. flexneri serotype conversion is
mediated by temperate bacteriophages [6,7]. Six different
serotype-converting phages or prophages, SfI, SfII, Sf6,
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ized [8-12], which can convert serotype Y to serotype
1a, 2a, 3b, 4a, 5a and X respectively [8-12]. Except for
Sf6 which carries a single gene, oac, for acetylation of
the O-antigen [13], the other phages carry three genes,
gtrA, gtrB,a n dgtrtype for O-antigen modification. The
first two gtr genes are highly conserved and interchange-
able in function, while the third gtr gene encodes a type-
specific glucosyltransferase responsible for the addition
of glucosyl molecules to sugar residue(s) on the basic
O-antigen repeating unit [9,12,14]. These phages inte-
grate into the S. flexneri host chromosome either at
tRNA-thrW downstream of proA [15] or at tRNA-argW
adjacent to yfdC [11]. Once integrated, the int and O-
antigen modification genes are located at the opposition
ends of the prophage genome, flanked by an attL
sequence on the left and an attR sequence on the right
[15].
Recently, untypeable or novel serotypes of S. flexneri
from natural infections had been reported worldwide
[5,16,17]. A novel serotype 1c was identified in Bangla-
desh in the late 1980s and was a predominant serotype
in Vietnam and other Asian countries [16,17]. Serotype
1c was a result of modification of serotype 1a with addi-
tion of a glucosyl group by a cryptic prophage carrying
a gtr1C gene cluster [18]. More recently, a new serotype
named as Xv emerged in China, and replaced 2a to
become the most prevalent S. flexneri serotype [5].
Although the antigenic determinant for the v variant is
not yet known, the phage SfX, which is responsible for
the group 7;8 antigenic determinant, was inducible from
the sequenced S. flexneri Xv strain 2002017 [5]. There-
fore emergence and spread of novel S. flexneri serotypes
in nature poses a significant public health threat globally
and in particular in developing countries where S. flex-
neri is the predominant cause of shigellosis.
In order to reveal possible roles played by the sero-
type-converting phages in the emergence of new sero-
types, and potential of emergence of novel serotypes
through this mechanism in nature, we performed infec-
tion assays using SfI and SfX, the 2 most common sero-
type-converting bacteriophages carried by S. flexneri
based on serotype frequency data [5,19]. We demon-
strate that a novel serotype, named serotype 1 d was
created in laboratory by infecting S. flexneri serotype X
strains with a SfI phage or by sequential infection of ser-
otype Y strain with SfX and SfI.
Results and discussion
Creation of a new serotype, serotype 1 d, through
serotype conversion with phages SfI and SfX
Using the procedures described by Mavris et al. [12], 2
serotype-converting phages, SfI and SfX, were induced
and isolated from S. flexneri serotype 1a strain 019 and
serotype Xv strain 2002017 respectively. The 2 phages
were then used to sequentially infect a serotype Y strain
036 in different order.
We first performed sequential infection in the order of
SfI and SfX. By infection with SfI, the S. flexneri sero-
type Y strain 036 was converted into serotype 1a
(036_1a), which agglutinated with both diagnostic typing
sera I and grouping sera 3;4 (also known as Y-5) as
shown in Table 1. Strain 036_1a was then used for
infection by SfX, but surprisingly, no plaques appeared,
indicating the strain cannot be infected by SfX.
Next we performed infection in the order of SfX and
SfI. The S. flexneri serotype Y strain 036 was converted
to serotype X by phage SfX infection, which aggluti-
n a t e do n l yw i t hs e r o t y p eX - s p e c i f i cg r o u p i n gs e r a7 ; 8 .
We named this strain as S. flexneri 036_X (Figure 1A
and 1B). When 036_X was further infected with phage
SfI, it was converted to a new serotype, which aggluti-
nated with both of the diagnostic serotype 1a-specific
typing sera I and serotype X-specific grouping sera 7;8,
and were negative for all other type and group-specific
sera (Figure 1A and 1B). The conventional serological
identification results were further confirmed by Wes-
tern-blot assay. As shown in Figure 1C, the lipopolysac-
charide (LPS) pattern of the newly constructed strain
was identical to that of serotype X strain 014 (Panel a,
Figure 1C) and that of serotype 1a strain 019 (Panel c,
Figure 1C), when probed by group specific sera 7;8 and
type specific sera I respectively. Since the original sero-
type Y strain and its SfI convertant 1a strain can aggluti-
nate with grouping sera 3;4, we also tested whether this
antigen is detectable in serotype 1 d. The LPS of the
new serotype was not recognized by the grouping sera
3;4 (Panel b, Figure 1C). Additionally, serotype-specific
genes, gtrX for phage SfX and gtrI for phage SfI, were
detected from these new strains by PCR and sequencing
of the PCR products.
S. flexneri serotype 1 has three known subtypes, 1a, 1b
and 1c, the agglutination patterns of which are defined
Table 1 Serological characterization of S. flexneri
serotype Y, X, 1a, 1b and 1c using serotyping
monoclonal antibodies (MASF)
Serotypes Reaction with MASF
Type antigen specific Group antigen specific 1c
I II IV-2 V VI B 3;4* 6 7;8 IV-1
Fy - - - - - + + - - - -
Fx - - - - - + - - + - -
F1a + - - - - + + - - - -
F1b + - - - - + - + - - -
F1c - - - - - + - - - - +
F1d + - - - - + - - + - -
*Y-5 is a synonym of grouping 3;4 antisera
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Page 2 of 6by a combination of typing and grouping sera, namely
typing sera I and grouping sera 3;4 (Y-5) for 1a, typing
sera I and grouping sera 6 for 1b, S. flexneri group anti-
gen specific MASF B and provisional specific monoclo-
nal antibody MASF1c for 1c [17] (Table 1). Since the
newly constructed serotype agglutinates with typing sera
I, but showed a different serological pattern from all
known serotype 1 subtypes (Table 1), we named this
new serotype 1 d.
In order to determine whether such serotype-convert-
ing events could occur in nature, we randomly selected
24 S. flexneri serotype X strains in our collection, and
infected them with serotype-converting phage SfI. All 24
strains tested were successfully converted to serotype 1 d.
We have no good explanation why serotype 1a strain
036_1a, constructed from 036 by infection with SfI,
could not be further infected by SfX. We randomly
selected 17 S. flexneri 1a isolates from our collection for
infection by SfX but found that none of them could be
infected by SfX. Clearly, the SfI can infect the strains
carrying serotype-converting phage SfX, but not vice
versa, likely due to phage immunity from modified O-
antigen receptors [20].
Interestingly, a recent study reported S. flexneri strains
with identical serological characteristics to the novel ser-
otype 1 d created in this study [21]. Four strains were
designated as untypeable serotype I: (7;8) among 467 S.
flexneri isolates collected in a passive surveillance pro-
ject from Henan, China in 2006 [21]. Thus it seems that
this novel serotype has already appeared in natural
infections. Although serotype 1 d represented less than
1% of the isolates, it would be important to monitor this
new serotype epidemiologically, considering that novel
S. flexneri serotypes such as 1c and Xv achieved its
dominance among the S. flexneri serotypes in a very
short time frame [5,16,17]
Agglutination test
3;4 7;8 I
036(Y) εε δ
036_X(X) ε δ ε
ε δ δ 036_1d(1d)
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014(X)
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Figure 1 Construction of a novel serotype, 1 d, of S. flexneri with serotype-converting bacteriophages SfX and SfI. (A) Illustration of
construction road map of S. flexneri 036_1d strain from a serotype Y strain 036, by sequential infection of phages SfX and SfI. (B) Serological
identification of S. flexneri 036_1d as serotype 1 d with agglutination test using monovalent diagnostic sera. The constructed strain S. flexneri
036_1d agglutinated with both of typing sera I and grouping sera7;8. (C) Serological identification of S. flexneri 036_1d by Western-blot assay.
The LPS extracted from the tested strains was separated by SDS-PAGE and hybridized with monovalent grouping sera 7;8 (a) and 3;4 (b), and
typing sera I (c), respectively. LPS of serotype X strain 014 and serotype 1a strain 019 were used as positive controls for group specific antigen
7;8 and type specific antigen I. After strain name in brackets is the serotype of the strain.
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host chromosome
It has been observed that the serotype-converting
phages, except for Sf6, usually integrate into the tRNA-
thrW gene of the host chromosome, which is adjacent
to proA upstream [15]. However, the gene downstream
the integrated phage have not been consistently identi-
fied [6,7]. Genomic analysis of S. flexneri serotype 2a
strain 301 (NC_004337), 2457 T (NC_004741) and sero-
type Xv strain 2002017 (CP001383) showed that the ser-
otype-converting phages were all integrated upstream of
host gene yaiC. Thus cross-bridging PCR analyses of S.
flexneri 036, 036_X, and 036_1d across the proA-yaiC
region were conducted using a series of primers and
found that both phages SfX and SfI were integrated into
the tRNA-thrW site, which is immediately downstream
of gene proA, and upstream of gene yaiC (Figure 2).
The phage SfI was found to be integrated immediately
upstream of SfX genome, with an att site at both ends
(Figure 2). By comparing the joining sequences between
the serotype-converting phage genomes, we found that
the phage SfI was integrated at the attL site of phage
SfX (see Additional file 1). The integration site for the
24 serotype X isolates converted by SfI was also found
to be the same site and thus it appears that the integra-
tion is very site specific.
Conclusions
A novel serotype 1 d was constructed by sequentially
infecting a serotype Y strain of S. flexneri with phage
SfX and SfI, or by infecting clinical serotype X isolates
with SfI. These results indicate that serotype conversion
with phages SfI and SfX could occur in nature. How-
ever, the observation that the order of infection by the 2
phages affects convertibility of a strain indicates that
serotype conversion is not only determined by the modi-
fication specific genes but also constrained by the
properties of the serotype-converting phages. Our find-
ings provide possible mechanisms how new serotypes of
S. flexneri could emerge in nature.
Methods
Bacterial strains and phages
S. flexneri strains and serotype-converting bacteriophages
used in this study were listed in Table 2. S. flexneri strain
036 (serotype Y) was used as host for phage infection and
large propagation. S. flexneri strains 014 (serotype X) and
019 (serotype 1a) were used as positive controls in the
serological assays for group specific antigen 7;8 and type
specific antigen I respectively. Twenty four S. flexneri ser-
otype X and 17 of S. flexneri serotype 1a strains isolated
from patients and stored at National Institute for Com-
municable Disease Control and Prevention, China CDC
(ICDC) were used for infection with serotype-converting
phages SfI and SfX respectively.
Serotype-converting bacteriophages SfI and SfX were
induced from S. flexneri serotype 1a strain 019 and sero-
type Xv strain 2002017 respectively, following the meth-
ods described by Mavris et al. [12].
Phage infection and lysogen isolation
We used the procedures described for lambda phage
(Fl) for phage infection [22]. S. flexneri cells were
inoculated into LB broth and incubated for 3 h at 37°C
with aeration. Cells were harvested by centrifugation at
4000 rpm and the cell density was adjusted to 2.0 OD
(A595 nm) with MgSO4 buffer (10 mmol/L). A proportion
of cells (200 μl) were infected with purified phages with
phage to bacterial cell ratio of about 1:1000 and incu-
bated for 20 min at 37°C. The infected cells were mixed
with 3 ml semisolid agar (Luria Broth (LB) with 0.7%
agar) and immediately spread on LB solid agar plates.
After incubation at 37°C for 20 h, the lysogens were
detected from turbid single colonies.
036(Y)
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036-1d(1d)
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proA
proA
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yaiC
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Figure 2 Genetic organization of prophage genomes of SfX and/or SfI in S. flexneri 036_X and 036_1d. The prophage genomes of SfX
and/or SfI are highlighted in yellow and pink respectively. The conserved genes of the host strain were shown in different colors: proA, gray;
yaiC, yellow; IS600 ORF1 and ORF2, brown; IS629 ORF1 and ORF2, orange; the putative integrase gene (int), white. The integration sites attB, attL
and attR are indicated in thick line. After strain name in brackets is the serotype of the strain.
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Serological identification was performed using two com-
mercial slide agglutination serotyping kits: monovalent
anti-sera (Denka Seiken, Japan) and monoclonal anti-
body reagents (Reagensia AB, Sweden) according to
manufacturer’s instructions. The new serotype was
further confirmed by Western-blot assay. Briefly, LPS
was prepared using the method of Hitchcock & Brown
[23] and transferred onto a PVDF membrane in a Tris/
glycine/methanol buffer. The membrane was blocked
with phosphate buffered saline (PBS) containing 5% (w/
v) skimmed milk and 0.05% Tween-20 and then incu-
bated with serotype X-specific monovalent grouping
sera 7;8 (Denka Seiken, Japan), serotype 1a-specific
monovalent typing sera I (Denka Seiken, Japan), or
monovalent grouping sera 3;4 (Denka Seiken, Japan).
The membrane was then washed with 1 × PBS contain-
ing 0.05% Tween-20, and incubated with a secondary
anti-rabbit antibody labeled with the fluorescent
IRDye™ 800 (Rockland). Fluorescence was detected
using an Odyssey Infrared Imaging System (LI-COR).
Identification of the integration site and orientation of
SfX and SfI
Based on previous studies showing that the integration
site of serotyping-conversion bacteriophages is con-
served [15], a series of primers were designed that were
located in genes proA, yaiC, gtrI, gtrX, intI and intX
across the presumptive integration region to determine
t h es i t ea n do r d e ro fi n t e g r a t i o nu s i n gP C R :proA-F,
ACAAAGCGAAATCATCCTCAA; intI-R, AGTGTTA-
CAGGAAATGGGAGGC. gtrI-F, ATTGAACGCCTC-
CTTGCTATGC; intX-R, TACGGTGGCTGCGTGA-
GAA. gtrX-F, TACCTTGACCCGTTTCCG; and yaiC-R,
GCAGGAAACCACCATCAACACC. PCR products
were sequenced commercially to identify the integration
site precisely.
Additional material
Additional file 1: Supplementary figure. DNA sequences of integration
sites in 036, 036_X and 036_1d, and bacteriophages SfI and SfX.
Sequences obtained by PCR and sequencing of junction regions using a
series of primers across the integration site as described in the text. (A)
attB in strain 036. (B) attP in phage SfI. (C) attP in phage SfX. (D) attL in
strain 036_X. (E) attR in 036_X and 036_1d. (F) Sequence between phage
SfI and SfX in strain 036_1d. Sequences in box are conserved DNA
regions between genes; Underlined sequences are tRNA-thrW; Sequences
in blue are att core sequence; Conserved genes flanking a given
integration site are shaded and their transcription orientation is marked
by an arrow.
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